Chemoradiotherapy, the standard of care for locally advanced non–small-cell lung cancer (NSCLC), often fails to eradicate all known disease. Despite advances in chemotherapeutic regimens, locally advanced NSCLC remains a difficult disease to treat, and locoregional failure remains common. Improved radiographic detection can identify patients at significant risk of locoregional failure after definitive treatment, and newer methods of escalating locoregional treatment may allow for improvements in locoregional control with acceptable toxicity. This review addresses critical issues in escalating local therapy, focusing on using serial positron emission tomography-computed tomography to select high-risk patients and employing stereotactic radio...
We aimed to review the development of the chemoradiotherapy options used in the treatment of locally...
Abstract Locally advanced non-small cell lung cancer (NSCLC) continues to be a challenging disease t...
Non-small cell lung cancer (NSCLC) is a heterogeneous disease accounting for approximately 85% of al...
Chemoradiotherapy, the standard of care for locally advanced non–small-cell lung cancer (NSCLC), oft...
Locally advanced Non-small cell lung cancer (NSCLC) is a commonly encountered diagnosis. Historicall...
AbstractApproximately a third of patients with newly diagnosed non-small cell lung cancer (NSCLC) ha...
The current standard of care for locally advanced non-small cell lung cancer (NSCLC) includes radiat...
The mainstay therapy for locally advanced non-small cell lung cancer is concurrent chemoradiotherapy...
The loco-regional control of NSCLC remains a major challenge but it is a requirement for cure: class...
The focus of this paper was to review and summarise the current issues and recent trends within the ...
Definitive radiochemotherapy is the standard treatment for many patients with locally advanced nonsm...
SummaryLung cancer remains a major challenge for radiation oncologists requiring a better treatment ...
AbstractLocally advanced non-small cell lung cancer (NSCLC) is a multifaceted disease that is challe...
Definitive radiochemotherapy is the standard treatment for many patients with locally advanced nonsm...
Radiation dose in the setting of chemo-radiation for locally advanced non-small cell lung cancer (NS...
We aimed to review the development of the chemoradiotherapy options used in the treatment of locally...
Abstract Locally advanced non-small cell lung cancer (NSCLC) continues to be a challenging disease t...
Non-small cell lung cancer (NSCLC) is a heterogeneous disease accounting for approximately 85% of al...
Chemoradiotherapy, the standard of care for locally advanced non–small-cell lung cancer (NSCLC), oft...
Locally advanced Non-small cell lung cancer (NSCLC) is a commonly encountered diagnosis. Historicall...
AbstractApproximately a third of patients with newly diagnosed non-small cell lung cancer (NSCLC) ha...
The current standard of care for locally advanced non-small cell lung cancer (NSCLC) includes radiat...
The mainstay therapy for locally advanced non-small cell lung cancer is concurrent chemoradiotherapy...
The loco-regional control of NSCLC remains a major challenge but it is a requirement for cure: class...
The focus of this paper was to review and summarise the current issues and recent trends within the ...
Definitive radiochemotherapy is the standard treatment for many patients with locally advanced nonsm...
SummaryLung cancer remains a major challenge for radiation oncologists requiring a better treatment ...
AbstractLocally advanced non-small cell lung cancer (NSCLC) is a multifaceted disease that is challe...
Definitive radiochemotherapy is the standard treatment for many patients with locally advanced nonsm...
Radiation dose in the setting of chemo-radiation for locally advanced non-small cell lung cancer (NS...
We aimed to review the development of the chemoradiotherapy options used in the treatment of locally...
Abstract Locally advanced non-small cell lung cancer (NSCLC) continues to be a challenging disease t...
Non-small cell lung cancer (NSCLC) is a heterogeneous disease accounting for approximately 85% of al...